Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. Issue 10 (12th July 2022)

• Record Type: Journal Article
• Authors: Vachher, Meenakshi; Bansal, Savita; Kumar, Bhupender; Yadav, Sandeep; Arora, Taruna; Wali, Nalini Moza; Burman, Archana
• Other Names: Rose‐John Stefan guestEditor.; Weiskirchen Ralf guestEditor.
• Is Part Of: Journal of cellular biochemistry. Volume 123:Issue 10(2022)
• Page Start: 1553
• Page End: 1584
• Publication Date: 2022-07-12
• Subjects: adipokines -- hepatocellular carcinoma -- hepatokines -- metabolic syndrome -- myokines -- nonalcoholic fatty liver disease -- nonalcoholic steatohepatitis -- obesity -- organokines; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.30252
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Globally the incidence of hepatocellular carcinoma (HCC) is on an upsurge. Evidence is accumulating that liver disorders like nonalcoholic fatty liver disease (NAFLD) and its more progressive form nonalcoholic steatohepatitis (NASH) are associated with increased risk of developing HCC. NAFLD has a prevalence of about 25% and 50%–90% in obese population. With the growing burden of obesity epidemic worldwide, HCC presents a major healthcare burden. While cirrhosis is one of the major risk factors of HCC, available literature suggests that NAFLD/NASH associated HCC also develops in minimum or noncirrhotic livers. Therefore, there is an urgent need to understand the pathogenesis and risk factors associated with NAFLD and NASH related HCC that would help in early diagnosis and favorable prognosis of HCC secondary to NAFLD. Adipokines, hepatokines and myokines are factors secreted by adipocytes, hepatocytes and myocytes, respectively, playing essential roles in cellular homeostasis, energy balance and metabolism with autocrine, paracrine and endocrine effects. In this review, we endeavor to focus on the role of these organokines in the pathogenesis of NAFLD/NASH and its progression to HCC to augment the understanding of the factors stimulating hepatocytes to acquire a malignant phenotype. This shall aid in the development of novel therapeutic strategies and tools for early diagnosis of NAFLD/NASH and HCC.